With prior tenures at the Bill and Melinda Gates Medical Research Institute and Merck Research Labs, David brings 20 years of experience in translational medicine and novel drug development to Abata's board.
David Kaufman joined Third Rock Ventures as a venture partner in 2020 and was promoted to partner in 2022.
He was previously chief medical officer and head of translational development at the Bill and Melinda Gates Medical Research Institute.
He helped establish the Gates MRI as a "nonprofit biotech," developing novel drugs and vaccines for tuberculosis, malaria, enteric diseases, neonatal health, and other global health challenges.
Previously, he led translational oncology at Merck Research Laboratories, where he oversaw immuno-oncology translational medicine, novel biomarker development, and global translational research partnering.
He joined Merck through the Merck Drug Development and Leadership Program, where he worked across vaccines, infectious diseases, and clinical oncology.
Prior to joining Merck, he was a physician in the Division of Infectious Diseases and the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and an Instructor in Medicine at Harvard Medical School.
He is a director of Hookipa Pharma and a director ex officio of the Society for the Immunotherapy of Cancer.
Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases.
Founded by pioneers in Treg biology, TCR and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine